Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Rhea-AI Summary

Moleculin Biotech (Nasdaq: MBRX), a Phase 3 clinical stage pharmaceutical company, has announced its participation in the LIVE! with Webull Corporate Connect: Healthcare Investment Webinar. Walter Klemp, Chairman and CEO of Moleculin, will present on Wednesday, August 28, 2024, at 3:40 PM ET.

Moleculin specializes in developing drug candidates for hard-to-treat tumors and viruses. This presentation offers an opportunity for investors and interested parties to gain insights into Moleculin's progress and future plans. The virtual event format allows for wide accessibility, potentially increasing investor engagement and visibility for the company.

Live webcast on Wednesday, August 28^th at 3:40 PM ET

HOUSTON, Aug. 26, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin will present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar on Wednesday, August 28, 2024 at 3:40 PM ET.

Conference Details:

Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Date/Time: Wednesday, August 28, 2024 at 3:40 PM ET 

Presenter: Walter Klemp, Chairman and Chief Executive Officer

Registration Link: HERE

About Webull Financial
Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.

About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as certain cancer indications. 

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-present-at-live-with-webull-corporate-connect-healthcare-investment-webinar-302229774.html

SOURCE Moleculin Biotech, Inc.

FAQ

When is Moleculin Biotech (MBRX) presenting at the Webull Corporate Connect Healthcare Investment Webinar?

Moleculin Biotech (MBRX) is presenting at the Webull Corporate Connect Healthcare Investment Webinar on Wednesday, August 28, 2024, at 3:40 PM ET.

Who will be representing Moleculin Biotech (MBRX) at the Webull Corporate Connect Healthcare Investment Webinar?

Walter Klemp, Chairman and Chief Executive Officer of Moleculin Biotech (MBRX), will be presenting at the Webull Corporate Connect Healthcare Investment Webinar.

What type of company is Moleculin Biotech (MBRX)?

Moleculin Biotech (MBRX) is a Phase 3 clinical stage pharmaceutical company focusing on developing drug candidates for hard-to-treat tumors and viruses.

How can investors attend Moleculin Biotech's (MBRX) presentation at the Webull Corporate Connect Healthcare Investment Webinar?

Investors can attend Moleculin Biotech's (MBRX) presentation by registering for the virtual event through the provided registration link in the press release.